Tetrahydrobiopterin Di-Hcl (sapropterin dihydrochloride)

Miscellaneous Powder (GRAM)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

Sapropterin dihydrochloride is the synthetic dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4), a cofactor in the metabolism of phenylalanine.

Sapropterin dihydrochloride is the synthetic dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). BH4 is the cofactor for phenylalanine 4-oxygenase (also known as phenylalanine hydroxylase), the enzyme that hydroxylates phenylalanine through an oxidative reaction to form tyrosine. In patients with phenylketonuria (PKU), phenylalanine 4-oxygenase activity is absent or deficient.

Sapropterin enhances activity of residual phenylalanine 4-oxygenase, which improves the normal oxidative metabolism of phenylalanine and thus decreases blood phenylalanine concentrations in some patients with PKU.

Generic name: sapropterin dihydrochloride
Therapeutic class: Chemicals-Pharmaceutical Adjuvants

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Tetrahydrobiopterin Di-Hcl

Intelligence content is not available yet.

Indications

No indications are available for this drug.

Dosing

The recommended initial dosage of sapropterin dihydrochloride for the treatment of PKU in adults is 10-20 mg/kg once daily. In pediatric patients, the recommended initial dosage is 10 mg/kg once daily (for those 1 month to 6 years of age) or 10-20 mg/kg once daily (for those 7 year of age or older).

Blood phenylalanine concentrations should be measured after 1 week of treatment and periodically for up to 1 month. In patients initiating therapy with a dosage of 10 mg/kg daily who do not respond with a decrease in blood phenylalanine concentrations after 1 month of treatment, dosage may be increased to 20 mg/kg once daily; if a response is still not obtained after 1 month of treatment at a dosage of 20 mg/kg once daily, the patient is deemed a nonresponder and therapy should be discontinued. In patients initiating therapy with a dosage of 20 mg/kg daily who do not respond with a decrease in blood phenylalanine concentrations after 1 month of treatment, the drug should be discontinued. Once responsiveness to sapropterin has been established, dosage may be adjusted within the range of 5-20 mg/kg once daily based on response to therapy as indicated by blood phenylalanine concentrations.

Drug interactions

In vitro studies indicate that sapropterin does not inhibit cytochrome P-450 (CYP) isoenzymes 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4/5, and does not induce CYP1A2, 2B6, or 3A4/5.

In vitro studies indicate that sapropterin does not inhibit organic anion transporter (OAT) 1 or 3, and multidrug and toxin extrusion transporter (MATE) 1 or 2K. Although sapropterin inhibits breast cancer resistance protein (BCRP) in vitro, the potential for clinically important interactions appears to be low. The drug does not appear to affect P-glycoprotein (P-gp) substrates.

Contraindications

Manufacturer states none known.

Adverse reactions

Adverse effects reported in 4% or more of patients receiving sapropterin in placebo-controlled studies include headache, rhinorrhea, pharyngolaryngeal pain, diarrhea, vomiting, cough, and nasal congestion.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data